search
Back to results

Bridge Reinvention

Primary Purpose

Spinal Cord Injuries

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
ReInventing Yourself after SCI
Sponsored by
Craig Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Spinal Cord Injuries focused on measuring self efficacy, participation, satisfaction with life

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. History of SCI at any level;
  2. completed initial inpatient rehabilitation but are no more than 6 months post-discharge;
  3. 18 years of age or older at the time of study enrollment;
  4. English speaking in order to complete study measures and participate in group interactions; and
  5. able to provide informed consent to participate.

Exclusion Criteria:

  1. History of moderate or severe traumatic brain injury;
  2. current participation in another RCT;
  3. live beyond a reasonable commuting distance from Craig Hospital;
  4. unable to verbally communicate;
  5. unable to attend group sessions;
  6. active participation in another formal clinical group or psychological therapy;
  7. are currently experiencing severe depression which would require more intense treatment than is provided in this intervention, as evidenced by a score of 20 or higher on the Personal Health Questionnaire-9;
  8. report any current suicidal ideation on the Personal Health Questionnaire-9; or
  9. have any condition that, in the judgment of the investigators, precludes successful participation in the study.

Sites / Locations

  • Craig Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Treatment

Control

Arm Description

Re-Inventing Yourself after SCI protocol - 6-week educational sessions

No intervention during course of study; participants offered the option of receiving the study intervention after completion of study.

Outcomes

Primary Outcome Measures

Change in Moorong Self-Efficacy Scale (MSES)
The MSES is a 16 item self-report measure of self-efficacy related to everyday life activities, designed specifically for persons with SCI. Individuals use a 7-point Likert scale ranging from 1 (very uncertain) to 7 (very certain) to rate their ability to perform 16 everyday tasks, with higher scores representing greater perceived self-efficacy. A Total Score, ranging from 16 to 112 is calculated by summing all item responses. The MSES has been used in previous studies of SCI, and demonstrates excellent internal consistency (alpha = 0.91 - 0.93), high reliability, and good convergent, concurrent and divergent validity. Time to administer: 5 to 10 minutes.

Secondary Outcome Measures

Change in Generalized Self-Efficacy Scale (GSES)
The GSES is a questionnaire designed to assess a person's ability to cope with a variety of difficult demands in life, with ten items scored using a Likert rating scale, ranging from 1 (not at all true) to 4 (exactly true). This scale has acceptable internal reliability (ranging from.73 to .90) and criterion validity, as demonstrated by positive correlations with positive emotions, optimism, and work satisfaction, and negative correlations with anxiety, stress, depression, and health complaints. The GSES has been used and validated in numerous populations and cultures, including people with SCI. This self-administered scale produces a Total Score ranging from 10-40, with higher scores indicating greater general self-efficacy. Time to administer: 3 to 5 minutes.
Change in Satisfaction with Life Scale (SWLS)
The SWLS is a five item measure on which respondents rate their life satisfaction using a 7-point Likert scale, ranging from 1 (strongly disagree) to 7 (strongly agree). A Total Score is calculated by summing each of the items, having a range of 5 to 35, with higher scores representing greater perceived quality of life. This measure has well established psychometric properties, with high reliability (.79 to .89), good content validity, criterion validity, and has been extensively used in research regarding people with SCI. Time to administer: 1 to 3 minutes.
Change in Participation Assessment with Recombined Tools - Objective (PART-O)
The PART-O is a 17-item assessment of participation and has demonstrated good psychometric properties in measuring participation for people living with disabilities. The PART-O has acceptable reliability and validity for persons with SCI. An Averaged Total Score is computed by taking the mean of 17 items, with scores ranging from 0 (never participate in these types of activities) to 5 (almost always participate in these types of activities), with higher scores representing greater participation. This assessment will be utilized to measure overall participation. Time to administer: 8 to 10 minutes.
Patient Health Questionnaire - 9 (PHQ-9)
The PHQ-9 is a 9 item scale that will be used to assess depression. Respondents rate the frequency at which specific problems have been bothersome during the past two weeks, using a four point scale ranging from 0 (not at all) to 3 (nearly every day). A total score is calculated by summing all items, with higher scores indicating an increasing severity of depression. This scale demonstrates excellent psychometrics, with excellent internal consistency (α = 0.86 - 0.89), high test-retest reliability (0.84) and good criterion and construct validity and has been used extensively in populations with SCI. Time to administer: 1 to 3 minutes.
Change in General Anxiety Disorder 7-item (GAD-7)
The GAD-7 is a brief 7 item measure that will be used to assess the severity of general anxiety. Using a four point Likert scale ranging from 0 (not at all sure) to 3 (nearly every day), respondents rate how often they have been bothered by specific symptoms during the past two weeks. A total severity score, ranging from 0 to 21, is calculated by summing all items. This measure has demonstrated high internal consistency (α = .89 - .92), good test-retest reliability (icc = .83) and adequate convergent and discriminant validity. This scale has been used in previous studies involving persons with SCI. Time to administer: 1 to 3 minutes.

Full Information

First Posted
May 30, 2018
Last Updated
June 11, 2018
Sponsor
Craig Hospital
Collaborators
The Craig H. Neilsen Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT03554733
Brief Title
Bridge Reinvention
Official Title
A Bridge From Rehabilitation to Real-World: Re-Inventing Yourself After SCI
Study Type
Interventional

2. Study Status

Record Verification Date
June 2018
Overall Recruitment Status
Completed
Study Start Date
April 1, 2014 (Actual)
Primary Completion Date
April 30, 2018 (Actual)
Study Completion Date
April 30, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Craig Hospital
Collaborators
The Craig H. Neilsen Foundation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal of this randomized controlled trial is to determine the efficacy of a treatment to improve resilience to stress for individuals with SCI who are transitioning from inpatient rehabilitation to home. The overarching hypothesis is that individuals who participate in an intervention that presents positive psychotherapy topics in an interactive, structured, cognitive-behaviorally-based group intervention that stresses restructuring maladaptive thought processes and provides experiential opportunities to reinforce behavioral change will demonstrate increased self-efficacy.
Detailed Description
The goal of this randomized controlled trial is to determine the efficacy of a treatment to improve resilience to stress for individuals with SCI who are transitioning from inpatient rehabilitation to home. The overarching hypothesis is that individuals who participate in an intervention that presents positive psychotherapy topics in an interactive, structured, cognitive-behaviorally-based group intervention that stresses restructuring maladaptive thought processes and provides experiential opportunities to reinforce behavioral change will demonstrate increased self-efficacy. There were three aims of this study: AIM 1: Self-Efficacy - To examine the ability of a six-week, manualized, cognitive-behaviorally based group educational intervention (Re-Inventing Yourself after SCI-Bridge) to improve both SCI-specific and general self-efficacy for people who are early in the process of community reintegration; AIM 2: Psychosocial Adjustment - To assess the ability of the Re-Inventing Yourself after SCI-Bridge intervention to improve psychosocial adjustment of people with SCI who are early in the community reintegration process; and, Aim 3: Participation - To determine the ability of the Re-Inventing Yourself after SCI-Bridge intervention to improve societal participation for people with SCI who are early in the community reintegration process.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spinal Cord Injuries
Keywords
self efficacy, participation, satisfaction with life

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Single-blind, waitlist-control
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
46 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment
Arm Type
Experimental
Arm Description
Re-Inventing Yourself after SCI protocol - 6-week educational sessions
Arm Title
Control
Arm Type
No Intervention
Arm Description
No intervention during course of study; participants offered the option of receiving the study intervention after completion of study.
Intervention Type
Behavioral
Intervention Name(s)
ReInventing Yourself after SCI
Intervention Description
6-week, manualized, cognitive-behaviorally based group educational intervention
Primary Outcome Measure Information:
Title
Change in Moorong Self-Efficacy Scale (MSES)
Description
The MSES is a 16 item self-report measure of self-efficacy related to everyday life activities, designed specifically for persons with SCI. Individuals use a 7-point Likert scale ranging from 1 (very uncertain) to 7 (very certain) to rate their ability to perform 16 everyday tasks, with higher scores representing greater perceived self-efficacy. A Total Score, ranging from 16 to 112 is calculated by summing all item responses. The MSES has been used in previous studies of SCI, and demonstrates excellent internal consistency (alpha = 0.91 - 0.93), high reliability, and good convergent, concurrent and divergent validity. Time to administer: 5 to 10 minutes.
Time Frame
Baseline, 6 weeks, 12 weeks, 18 weeks
Secondary Outcome Measure Information:
Title
Change in Generalized Self-Efficacy Scale (GSES)
Description
The GSES is a questionnaire designed to assess a person's ability to cope with a variety of difficult demands in life, with ten items scored using a Likert rating scale, ranging from 1 (not at all true) to 4 (exactly true). This scale has acceptable internal reliability (ranging from.73 to .90) and criterion validity, as demonstrated by positive correlations with positive emotions, optimism, and work satisfaction, and negative correlations with anxiety, stress, depression, and health complaints. The GSES has been used and validated in numerous populations and cultures, including people with SCI. This self-administered scale produces a Total Score ranging from 10-40, with higher scores indicating greater general self-efficacy. Time to administer: 3 to 5 minutes.
Time Frame
Baseline, 6 weeks, 12 weeks, 18 weeks
Title
Change in Satisfaction with Life Scale (SWLS)
Description
The SWLS is a five item measure on which respondents rate their life satisfaction using a 7-point Likert scale, ranging from 1 (strongly disagree) to 7 (strongly agree). A Total Score is calculated by summing each of the items, having a range of 5 to 35, with higher scores representing greater perceived quality of life. This measure has well established psychometric properties, with high reliability (.79 to .89), good content validity, criterion validity, and has been extensively used in research regarding people with SCI. Time to administer: 1 to 3 minutes.
Time Frame
Baseline, 6 weeks, 12 weeks, 18 weeks
Title
Change in Participation Assessment with Recombined Tools - Objective (PART-O)
Description
The PART-O is a 17-item assessment of participation and has demonstrated good psychometric properties in measuring participation for people living with disabilities. The PART-O has acceptable reliability and validity for persons with SCI. An Averaged Total Score is computed by taking the mean of 17 items, with scores ranging from 0 (never participate in these types of activities) to 5 (almost always participate in these types of activities), with higher scores representing greater participation. This assessment will be utilized to measure overall participation. Time to administer: 8 to 10 minutes.
Time Frame
Baseline, 6 weeks, 12 weeks, 18 weeks
Title
Patient Health Questionnaire - 9 (PHQ-9)
Description
The PHQ-9 is a 9 item scale that will be used to assess depression. Respondents rate the frequency at which specific problems have been bothersome during the past two weeks, using a four point scale ranging from 0 (not at all) to 3 (nearly every day). A total score is calculated by summing all items, with higher scores indicating an increasing severity of depression. This scale demonstrates excellent psychometrics, with excellent internal consistency (α = 0.86 - 0.89), high test-retest reliability (0.84) and good criterion and construct validity and has been used extensively in populations with SCI. Time to administer: 1 to 3 minutes.
Time Frame
Baseline, 6 weeks, 12 weeks, 18 weeks
Title
Change in General Anxiety Disorder 7-item (GAD-7)
Description
The GAD-7 is a brief 7 item measure that will be used to assess the severity of general anxiety. Using a four point Likert scale ranging from 0 (not at all sure) to 3 (nearly every day), respondents rate how often they have been bothered by specific symptoms during the past two weeks. A total severity score, ranging from 0 to 21, is calculated by summing all items. This measure has demonstrated high internal consistency (α = .89 - .92), good test-retest reliability (icc = .83) and adequate convergent and discriminant validity. This scale has been used in previous studies involving persons with SCI. Time to administer: 1 to 3 minutes.
Time Frame
Baseline, 6 weeks, 12 weeks, 18 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: History of SCI at any level; completed initial inpatient rehabilitation but are no more than 6 months post-discharge; 18 years of age or older at the time of study enrollment; English speaking in order to complete study measures and participate in group interactions; and able to provide informed consent to participate. Exclusion Criteria: History of moderate or severe traumatic brain injury; current participation in another RCT; live beyond a reasonable commuting distance from Craig Hospital; unable to verbally communicate; unable to attend group sessions; active participation in another formal clinical group or psychological therapy; are currently experiencing severe depression which would require more intense treatment than is provided in this intervention, as evidenced by a score of 20 or higher on the Personal Health Questionnaire-9; report any current suicidal ideation on the Personal Health Questionnaire-9; or have any condition that, in the judgment of the investigators, precludes successful participation in the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jennifer Coker, MPH
Organizational Affiliation
Craig Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Craig Hospital
City
Englewood
State/Province
Colorado
ZIP/Postal Code
80113
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Bridge Reinvention

We'll reach out to this number within 24 hrs